Search

Your search keyword '"Ferrer Marín, Francisca"' showing total 44 results

Search Constraints

Start Over You searched for: Author "Ferrer Marín, Francisca" Remove constraint Author: "Ferrer Marín, Francisca" Database Unpaywall Remove constraint Database: Unpaywall
44 results on '"Ferrer Marín, Francisca"'

Search Results

1. Author Correction: Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA

2. e14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and Sustained Deep Molecular Response

3. Genomic classification and outcomes of young patients with polycythemia vera and essential thrombocythemia according to the presence of splanchnic vein thrombosis and its chronology

4. NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy

5. DNMT3A/TET2/ASXL1 mutations are an age-independent thrombotic risk factor in polycythemia vera patients: an observational study

6. PB1962: INFLUENCE OF TRANSCRIPT TYPES IN SUSTAINED DEEP MOLECULAR RESPONSE (SDMR) AND TREATMENT-FREE REMISSION (TFR) IN CHRONIC PHASE-CHRONIC MYELOID LEUKEMIA (CP-CML) PATIENTS TREATED WITH TKI

7. P987: IRAK1 AND JAK2 DUAL INHIBITION WITH PACRITINIB PREVENTS MYELOFIBROSIS-LIKE PHENOTYPE IN AN INFLAMMATION-DRIVEN MURINE MODEL

8. P990: NF-ΚB AND JAK/STAT PATHWAYS INHIBITION REVERSES FIBROSIS IN A MURINE MODEL OF INFLAMMATION-DRIVEN MYELOFIBROSIS

9. P680: PONATINIB 15 MG AS CONSOLIDATION PRIOR TO TREATMENT FREE REMISSION IN CHRONIC MYELOID LEUKEMIA

10. CNL and aCML should be considered as a single entity based on molecular profiles and outcomes

11. CAPN1 (Calpain1)-Dependent Cleavage of STIM1 (Stromal Interaction Molecule 1) Results in an Enhanced SOCE (Store-Operated Calcium Entry) in Human Neonatal Platelets

13. Association between Germline Single-Nucleotide Variants in ADME Genes and Major Molecular Response to Imatinib in Chronic Myeloid Leukemia Patients

14. Tyrosine kinase inhibitor dose reduction during the management of accelerated phase chronic myeloid leukemia

15. Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA

17. Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients

18. Qualitative and Quantitative Comparison of Plasma Exosomes from Neonates and Adults

20. The risk of thrombosis in essential thrombocythemia is associated with the type of CALR mutation: A multicentre collaborative study

22. Características clínico-biológicas de los pacientes con mielofibrosis: un análisis de 1.000 casos del Registro Español de Mielofibrosis

23. Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis

25. Developmental Differences in Platelet Inhibition Response to Prostaglandin E1

27. Essential thrombocythaemia with mutation in MPL: clinicopathological correlation and comparison with JAK2V617F-mutated and CALR-mutated genotypes

28. Significant Hypo-Responsiveness to GPVI and CLEC-2 Agonists in Pre-Term and Full-Term Neonatal Platelets and following Immune Thrombocytopenia

29. Prognostic risk models for transplant decision-making in myelofibrosis

31. Comprehensive comparison of neonate and adult human platelet transcriptomes

32. Identification of two novel mutations in RASGRP2 affecting platelet CalDAG-GEFI expression and function in patients with bleeding diathesis

33. PTCH1 is a reliable marker for predicting imatinib response in chronic myeloid leukemia patients in chronic phase

34. Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis

35. Down Regulation of the Munc18b-syntaxin-11 Complex and β1-tubulin Impairs Secretion and Spreading in Neonatal Platelets

36. Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea

38. Long-term results of prednisone treatment for the anemia of myelofibrosis

39. Risk factors for non‐melanoma skin cancer in patients with essential thrombocythemia and polycythemia vera

40. An atypical IgM class platelet cold agglutinin induces GPVI-dependent aggregation of human platelets

41. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea

42. Leukemic transformation driven by an ASXL1 mutation after a JAK2V617F-positive primary myelofibrosis: clonal evolution and hierarchy revealed by next-generation sequencing

44. Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera

Catalog

Books, media, physical & digital resources